title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,FMTX,0.005467,Neutral,0.088737
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,FMTX,0.00644,Somewhat-Bearish,-0.247008
Stocks That Hit 52-Week Lows On Monday,20220613T161842,https://www.benzinga.com/markets/options/22/06/27677156/52-weeks-high-and-low-article,FMTX,0.005366,Neutral,0.001984
Stocks That Hit 52-Week Lows On Tuesday,20220524T161351,https://www.benzinga.com/markets/options/22/05/27375519/52-weeks-high-and-low-article,FMTX,0.010175,Neutral,0.079813
Stocks That Hit 52-Week Lows On Wednesday,20220427T184104,https://www.benzinga.com/markets/options/22/04/26844275/52-weeks-high-and-low-article,FMTX,0.006956,Neutral,0.000342
Stocks That Hit 52-Week Lows On Monday,20220314T161153,https://www.benzinga.com/news/22/03/26125409/stocks-that-hit-52-week-lows-on-monday,FMTX,0.003772,Neutral,0.00355
"Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial",20220803T141314,https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f,FMTX,0.098659,Somewhat-Bullish,0.220278
